CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Zalicus
Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain, today
announced that Zalicus management will present at the Oppenheimer 23rd
Annual Healthcare Conference at 1:00 p.m. ET on Wednesday December 12,
2012 at the Waldorf Astoria in New York. Interested parties may access a
live webcast of the presentation by visiting the Zalicus website at www.zalicus.com.
The webcast will be archived on the Zalicus website following the event.
About Zalicus
Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from
pain. Zalicus has a portfolio of proprietary clinical-stage product
candidates targeting pain such as Z160 and Z944, and has entered into
multiple revenue-generating collaborations with large pharmaceutical
companies relating to other products, product candidates and drug
discovery technologies. Zalicus applies its expertise in the discovery
and development of selective ion channel modulators and its combination
high throughput screening capabilities to discover innovative
therapeutics for itself and its collaborators in the areas of pain,
inflammation, oncology and infectious disease. To learn more about
Zalicus, please visit www.zalicus.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Zalicus, its product candidates, their potential, and its
plans for clinical development. These forward-looking statements about
future expectations, plans, objectives and prospects of Zalicus and its
product candidates may be identified by words like "believe," "expect,"
"may," "will," "should," "seek," “plan” or “could” and similar
expressions and involve significant risks, uncertainties and
assumptions, including risks related to the clinical development of its
product candidates, the unproven nature of the Zalicus Ion channel drug
discovery technology, and those other risks that can be found in the
"Risk Factors" section of Zalicus' annual report on Form 10-K on file
with the Securities and Exchange Commission and the other reports that
Zalicus periodically files with the Securities and Exchange Commission.
Actual results may differ materially from those Zalicus contemplated by
these forward-looking statements. These forward-looking statements
reflect management's current views and Zalicus does not undertake to
update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this
release except as required by law.
(c) 2012 Zalicus Inc. All rights reserved.
